425: Quanterix Announces Q4 2024 Financial Results and Akoya Biosciences Acquisition

Quanterix reports 11% revenue growth for Q4 2024 and highlights the planned acquisition of Akoya Biosciences to expand its market presence.

Summary

• Quanterix Corporation announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company reported an 11% increase in revenue for the fourth quarter, reaching $35.2 million compared to $31.5 million in the prior year.
• GAAP gross margin for the quarter was 63.0%, up from 61.5% in the prior year, while adjusted gross margin was 57.7%, compared to 54.7% in the prior year.
• The net loss for the quarter was $11.6 million, compared to a net loss of $8.8 million in the prior year.
• Net cash usage during the quarter was $4.4 million, compared to $6.4 million in the prior year.
• Quanterix ended 2024 with $291.7 million in cash, cash equivalents, marketable securities, and restricted cash.
• For the full year 2024, revenue increased by 12% to $137.4 million, compared to $122.4 million in the prior year.
• The full year net loss was $38.5 million, a decrease of $10.2 million compared to the prior year.
• Net cash usage for the year was $32.2 million, compared to $17.4 million in the prior year.
• The company expects 2025 revenue to be in the range of $140.0 million to $146.0 million, representing growth of 2% to 6% over 2024.
• Quanterix anticipates 2025 cash usage to be approximately $55.0 million to $65.0 million, including $20.0 million of upfront payments for the EMISSION acquisition.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the revenue growth, strategic acquisition, and new product launches. However, the net loss and relatively low 2025 revenue growth guidance temper the overall outlook.

Positives

• Quanterix delivered its seventh consecutive quarter of double-digit revenue growth.
• The acquisition of Akoya Biosciences is expected to create an integrated solution for biomarker detection.
• The launch of Simoa ONE is anticipated to enhance sensitivity and workflow efficiency.
• The acquisition of EMISSION secures a key component for the Simoa ONE platform.
• The FDA Breakthrough Designation for LucentAD Complete highlights progress in Alzheimer's disease testing.
• GAAP gross margin of 63.0% for Q4 2024, as compared to 61.5% in the prior year.
• Adjusted gross margin (non-GAAP) of 57.7% as compared to 54.7% in the prior year.
• Net loss of $38.5 million for the full year 2024, a decrease of $10.2 million compared to the prior year.

Negatives

• The net loss for Q4 2024 was $11.6 million, compared to a net loss of $8.8 million in the prior year.
• Net cash usage during the year was $32.2 million, compared to net cash usage of $17.4 million in the prior year.
• The company expects revenue growth of only 2% to 6% in 2025.

Risks

• The company faces risks associated with the anticipated timing and features of the Simoa ONE launch.
• There are risks that Quanterix may fail to realize the anticipated benefits and synergies of its acquisition of Emission, Inc.
• Quanterix's estimates regarding expenses, future revenues, capital requirements, and needs for additional financing could be incorrect.
• The company faces risks related to the restatement of its consolidated financial statements, including increased costs and the possibility of legal proceedings.
• There are risks related to Quanterix's ability to maintain effective internal control over financial reporting.
• The company faces risks related to the potential dilutive effect of shares of Quanterix common stock to be issued in the Merger.

Future Outlook

Quanterix expects 2025 revenue to be in the range of $140.0 million to $146.0 million, representing growth of 2% to 6% over 2024. The company anticipates 2025 cash usage to be approximately $55.0 million to $65.0 million, including $20.0 million of upfront payments for the EMISSION acquisition.

Management Comments

• Masoud Toloue, Chief Executive Officer of Quanterix, stated that the company delivered 11% revenue growth in Q4 despite a capital constrained environment.
• He attributed the growth to investments in the business model, focusing on key vertical markets and recurring revenues.
• He also mentioned the expansion of their approach to immunology and oncology to grow the addressable market.
• The acquisition of Akoya Biosciences was described as an important step forward in the execution of this strategy.

Industry Context

The acquisition of Akoya Biosciences reflects a trend towards consolidation and integrated solutions in the life sciences and diagnostics industry. Companies are seeking to offer comprehensive platforms that combine different technologies to provide more value to customers and accelerate the development of new clinical tests. Quanterix's focus on ultra-sensitive biomarker detection positions it well in the growing market for precision medicine and personalized healthcare.

Comparison to Industry Standards

• Quanterix's revenue growth of 11% in Q4 2024 is comparable to other companies in the life sciences and diagnostics industry, such as Bio-Techne, which reported organic growth of 9% in its most recent quarter.
• The company's adjusted gross margin of 57.7% is in line with industry averages, but there is room for improvement as companies like Illumina have gross margins above 70%.
• The planned acquisition of Akoya Biosciences is similar to other recent deals in the industry, such as Danaher's acquisition of Abcam, which aims to expand their product offerings and market reach.
• Quanterix's focus on Alzheimer's disease testing aligns with the growing interest in early detection and diagnosis of neurodegenerative diseases, as seen with companies like C2N Diagnostics and their PrecivityAD blood test.

Stakeholder Impact

• Shareholders can expect potential long-term value creation from the Akoya Biosciences acquisition and new product launches.
• Employees may experience integration-related changes and opportunities for growth within the combined company.
• Customers will benefit from the integrated solutions and enhanced capabilities offered by Quanterix and Akoya.
• Suppliers may see increased demand for their products and services as Quanterix expands its operations.
• Creditors should be reassured by the company's strong cash position and commitment to financial discipline.

Next Steps

• Complete the acquisition of Akoya Biosciences, expected in the second quarter of 2025.
• Launch Simoa ONE instrument by the end of 2025.
• Integrate EMISSION's technology into the Simoa ONE platform.
• Continue to expand partnerships for Alzheimer's disease testing.
• Focus on key vertical markets and recurring revenues to drive future growth.

Key Dates